Technology > Therapeutic drSH3 targets

Next Biomed Therapies Oy is developing drSH3 domains targeted against a wide variety of therapeutically relevant proteins from different functional classes.

Fusion of these drSH3 molecules with themselves or existing therapeutic antibodies enables convenient construction in a plug-and-play fashion of powerful multi-specific proteins that can bind to several target proteins within and between these functional classes.

See here for examples of multi-specific drSH3-IgG fusion strategies

drSH3 = double-randomized SH3